Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)

BACKGROUND: Patients with high-frequency episodic migraine (HFEM) have a greater disease burden than those with low-frequency episodic migraine (LFEM). Acute treatment overuse increases the risk of migraine chronification in patients with HFEM. Galcanezumab, a humanized monoclonal antibody binding c...

Descripción completa

Detalles Bibliográficos
Autores principales: Silberstein, Stephen D., Stauffer, Virginia L., Day, Katie A., Lipsius, Sarah, Wilson, Maria-Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734504/
https://www.ncbi.nlm.nih.gov/pubmed/31253091
http://dx.doi.org/10.1186/s10194-019-1024-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734504/
https://www.ncbi.nlm.nih.gov/pubmed/31253091
http://dx.doi.org/10.1186/s10194-019-1024-x

Ejemplares similares